Indiana University Vector Production Facility

Indianapolis, IN

Profile last updated: 2026-03-21

National Center

AAV Lentiviral

No confirmed program data — ClinicalTrials.gov verification pending · Last scored 2026-09-07

66.3

Signal Score

○ FDA Inspections ✓ Clinical Trials (49) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Indiana University Vector Production Facility

Signal Score: 66.3/100 (as of 2026-09-07)
Quality Compliance: Assessment pending
Headquarters: Indianapolis, IN
Modalities: AAV, Lentiviral
Active Programs: Data pending
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

About Indiana University Vector Production Facility

CDMO.

Signal Score & Pillar Breakdown

Scores are being republished. Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.

Quality Compliance —

No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.

FDA InspectionsNo US records on file

Operations

Programs — no verified data

Sponsors— no verified data

ModalitiesAAV, Lentiviral

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

NCT07168785 [18F]-AraG PET Imaging in LA HNSCC EARLY_PHASE1 Not Yet Recruiting

NCT07761910 Prospective Study on Radiation Induced Cardiotoxicity... PHASE2 Recruiting

NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 NA Recruiting

NCT07708714 Optimizing Hydroxyurea Therapy in Children With Sickle Cell... PHASE1/PHASE2 Recruiting

NCT07640139 Estimating the Impact of Obesity Medications on Clinical and... NA Enrolling By Invitation

NCT06915038 ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx NA Recruiting

NCT06508827 Intravenous Iron in Combination With Standard of Care... PHASE2 Withdrawn

NCT06513663 Exercise as Maintenance Therapy in Advanced Lung Cancer NA Terminated

NCT05757843 Using Circulating Tumor DNA to Personalize Duration of... PHASE2 Withdrawn

NCT05899166 Carbohydrate Beta Cell Function and Glucose Control in... NA Recruiting

View all 49 programs →

Source: ClinicalTrials.gov · Retrieved Oct 06, 2026

Financial Stability

Profile-based financial assessment

SEC FilingsPrivate company

Capacity

Profile-based capacity assessment

Clinical Activity 49 studies

NCT07168785 [18F]-AraG PET Imaging in LA HNSCC EARLY_PHASE1 Not Yet Recruiting NCT07761910 Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for... PHASE2 Recruiting NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 NA Recruiting NCT07708714 Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In... PHASE1/PHASE2 Recruiting NCT07640139 Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes NA Enrolling By Invitation NCT06915038 ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx NA Recruiting NCT06508827 Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma PHASE2 Withdrawn NCT06513663 Exercise as Maintenance Therapy in Advanced Lung Cancer NA Terminated NCT05757843 Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab PHASE2 Withdrawn NCT05899166 Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes NA Recruiting NCT05460468 Neuromodulation of Memory in Aging NA Recruiting NCT06511453 Acupressure in Patients With Sickle Cell Disease NA Active Not Recruiting NCT04402593 Music Therapy For The Treatment Of Cisplatin Induced Tinnitus In Patients... NA Withdrawn NCT05783297 Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV... NA Completed NCT05100342 Prospective Validation of a Points Score System Predicting 30-day Survival NA Recruiting NCT05119036 Adjuvant Treatment Deintensification After Transoral Surgery for Human... NA Completed NCT05251337 Use of Aromatherapy to Reduce Symptom Burden PHASE2 Completed NCT03321760 SABR for T1-2a N1 NSCLC PHASE2 Withdrawn NCT04930055 Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC) NA Terminated NCT05045820 Integrative Medicine in Pain Management in Sickle Cell Disease NA Active Not Recruiting

+ 29 more studies

Source: ClinicalTrials.gov · Retrieved Oct 06, 2026

Frequently Asked Questions About Indiana University Vector Production Facility

How many clinical programs is Indiana University Vector Production Facility linked to?

Indiana University Vector Production Facility is associated with 49 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.

What is Indiana University Vector Production Facility's CDMO Signal Score?

Indiana University Vector Production Facility has a Signal Score of 66/100, based on quality, operations, financial stability, and capacity data.

Evaluating Indiana University Vector Production Facility for a manufacturing program?

Use the free AI matchmaker to compare Indiana University Vector Production Facility against other CDMOs by FDA, EMA, and clinical-trial data — no login required.

Find & compare CDMOs →

Represent this organization? Contact us to verify or update this profile.

See all CDMOs in:

AAV CDMOs → Lentiviral CDMOs →